Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
Last Updated On 27 Dec
Always recalculate concentration when changing vial sizes
Human studies published in 2002 demonstrated weight loss and significant decreases in blood glucose levels without hypoglycemia
Improves Insulin Sensitivity Insulin resistance is linked to hypertension as it causes vascular inflammation and constriction of blood vessels
Insulin resistance can cause blood sugar levels to remain high and excess sugar to be stored in the body as fat
